# CENTER OF EXCELLENCE IN ENVIRONMENTAL TOXICOLOGY (CEET)

# Environmental Health Science Focused Research Pilot Project Grants

Grants up to \$50,000 available per project

Supported by the National Institute of Environmental Health Sciences (NIEHS) Grant #2 P30 ES013508

## **Application Packet**

## **Background**

The <u>Center of Excellence in Environmental Toxicology</u> (CEET) announces the following <u>Focused Research</u> pilot project opportunity.

Applications are due by Monday, August 30, 2021.

#### **Focus Research Awards:**

Applications related to the following four (4) thematic areas are currently being accepted:

- 1. Air Pollution and Lung Health
- 2. Environmental Exposures and Cancer
- 3. Windows-of-Susceptibility
- 4. Environmental Neuroscience

Applicants who submitted in a previous funding cycle and were unfunded and encouraged in their decision letter may submit a revised application.

# **Deadlines and Notifications**

All applications will be sent out for peer-review to experts in the field, the CEET Executive Committee will then meet to select the awardees. Each application will be scored using the NIH scoring system (refer to the 'application review criteria' section). Below are the application deadlines and timeline.

Application Deadline	CEET Executive Committee Meeting	Award Notification	Award Start Date
By Monday	By Friday	By Friday	Friday,
August 30, 2021	September 17, 2021	September 24, 2021	October 1, 2021

Environmental Health Science Focused Research Pilot Project Grant Application

## **Eligibility Requirements**

- 1. Any standing or research faculty member from any University of Pennsylvania School may apply
- 2. Preference will be given to first-time applicants and senior faculty who wish to embrace environmental health or toxicology research as a new direction
- 3. Preference will be given to applications that are likely to lead to grant funding from the National Institute of Environmental Health Sciences (NIEHS)
- 4. Preference will be given to research projects that will utilize one or more of the CEET Facility Cores
  - Integrative Health Sciences Facility Core
  - Translational Biomarker Core
  - Exposure Biology Informatics Core
- 5. The research being proposed cannot be funded by an external funding agency

## **Funding/Reporting Requirements**

The anticipated period of funded project performance will be for 12 months following the project start date.

Funded applications <u>must</u> meet the following compliance guidelines.

- 1. All IRB and IACUC protocols must be in place before the funding can be awarded. A copy of the approved protocols and approval letter should be submitted to the CEET before an award notice can be issued. For more information, see 'IRB and IACUC' in the Full Application Instructions section below.
- 2. Submit an annual progress report within 3 months of the end of the funding period The progress report should follow the same format as that required for an NIH R01 RPPR-progress report
- 3. Present your findings at a CEET Pilot-Project Progress Seminar within 6 months of the end of the funding cycle
- 4. Acknowledge the parent P30 grant on all publications with the following language: "This publication was made possible by P30 ES013508 from the National Institute of Environmental Health Sciences, NIH. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NIEHS, NIH." It is the responsibility of the P.I to ensure that all papers resulting from the pilot project are submitted to PubMed Central and assigned a PMCID number

## **Full Application Instructions:**

Applications must be submitted in <u>a single PDF</u> for internal review to <u>paula.williams@pennmedicine.upenn.edu</u>. Applications should include the following, in this order:

- 1. Application Form (see attached below)
- 2. New Format NIH Biosketch for the P.I. and other co-investigators (limit 5 pages)
- 3. An abstract a brief summary of the project (no more than 300 words)
- 4. Introduction-<u>Revised Applications Only</u>. These must include a one page response to the previous critique; and then follow the instructions below.
- 5. Specific Aims (not more than 1 page) concise goals of the proposed research and a summary of expected outcomes, including specific objectives
- 6. Research Strategy (not more than 6 pages)
  - <u>Significance</u> describe the importance of the problem or critical barrier that the project addresses in Environmental Health Sciences, and explain how the project will improve scientific knowledge, technical capability, or clinical practice if the proposed aims are achieved

Environmental Health Science Focused Research Pilot Project Grant Application

- <u>Innovation</u> describe how the proposed research seeks to shift research practice paradigms and how any methodologies or theoretical concepts that are being developed or used in the project may have an advantage over existing practices
- <u>Approach</u> describe the overall strategy, methodology, and analyses to be used to accomplish specific aims, including how data will be collected. Discuss potential problems, alternative strategies, and benchmarks of success
- Statistical Plan and Plan for Scientific Rigor & Reproducibility
- 7. Project Timeline (1 page) a proposed timeline of study performance should be included, identifying specific tasks and milestones in project progress for the 12-month period of performance
- 8. A brief outline of how the results from the pilot study will enable the submission of a subsequent NIEHS/NIH grant and a detailed plan for this subsequent grant submission (not more than 1 page)
- 9. Separate List of Current and Pending Grant Support using NIH formatting guidelines (NOTE: this should be a separate document in addition to the Biosketch)
- 10. References
- 11. Budget an NIH-style budget table of personnel, equipment, supplies, and other estimated costs to perform the proposed project. Travel is not allowed.
- 12. Budget Justification a detailed explanation and justification of the funding request. *Non-allowable expenses include:* 
  - Faculty salaries
  - Tuition for graduate students
  - Travel expenses
- 13. Facility Core Usage and Correspondence The CEET Facility Cores offer technical and research support to Center investigators and Pilot Project awardees. A wide range of capabilities, including biostatistical support, analytical sample preparation/processing, and biological sample measurements are available. Early discussion with Core Directors is strongly encouraged. For information on The CEET's cores and their directors, please click here. CEET Facility Core Directors should be contacted to provide a letter of support as a part of this application. NOTE: If CEET Facility Cores are NOT proposed to support Pilot Project performance, a written justification must be provided as a part of the application.

## **IRB** and **IACUC**

Applications using Vertebrate Animals or Human Subjects must also submit the corresponding sections required in an NIH grant (**see below**). Failure to do so will lead to the application being not considered for funding.

### Vertebrate Animals:

- 1. Proposed Use of Animals
- 2. Justification for the Use of Animals
- 3. Veterinary Care
- 4. Procedures
- 5. Method of Euthanasia

#### Protection of Human Subjects

Please completed the Human Subjects form below along with all attachments. (see attached below)

<u>Center of Excellence in Environmental Toxicology (CEET)</u>

<u>Environmental Health Science Focused Research Pilot Project Grant Application</u>

# **Application Form (Please Type)**

Name						
Position/Title						
Department						
Please select applicable research	area	Air Pollu	Air Pollution & Lung Health (AP)			
		Environm	nental Exposures and C	ancer (EC)		
		Windows-of- Susceptibility (WS)				
		Environm	nental Neuroscience (El	N)		
		Opportun	ity Award - Please Lis	t Research Area		
Preferred Phone Number		· <del></del>	Preferred Email			
Preferred Mailing Address						
Application/Research Title						
Total Funding Amount Being R	equested					
Name and Contact Information	of					
Business or Grant Administrator	r					
		Questi	onnaire			
Are you a CEET Member?		Yes		No		
If CEET Member, please list yo	ur					
Thematic Area(s)						
Are you an Early State Investigator?		Yes		No		
Do you plan to use a CEET Facility		Yes		No		
Core?						
If so, please indicate which Core	e(s) you	Integrative Health Sciences Facility Core (IHSFC)				
plan to use?		Translational Biomarker Core				
		The E	Exposure Biology Information	matics Core		
Have you met with a Core Director?		Yes	No			
If yes, please list of names of the						
individuals that you have met w	ith?					
Is a letter of support from a Core		Yes	_No			
Director included with this pack						
If you <b>do not</b> plan on using a Cl	EET					
Facility Core, please provide a v	vritten					
justification here.						
Are there animals included in this study?		Yes	No			
Are humans Subjects included in this		Yes	No			
study?						
Application Check List						
Please provide a 'check' or 'x' r	ext to eve	ry item that is	included in this applica			
Application Form	Biosketc	h	Abstract	Specific Aims		
Preliminary Studies	Methods		Research Strategy	Project Timeline		
			Statistical Plan			
Future Funding Statement	Grant Su	pport List	References	Budget/Budget		
				Justification		
Facility Core Letter of Support	Applicab		Applicable IACUC			
	Approva	1	Approval			

Environmental Health Science Focused Research Pilot Project Grant Application

### Human Subjects Questionnaire

Please answer all questions below. Note that some questions require attachments. Please use additional paper as needed to answer questions. NOTE: If your study does not include human subjects, please answer 'no' to question number one. There is no need to answer other questions.

Title of Application		
Name		
Position		
Tit		
	ntact Information	
Stu	dy Title	
	SECTION 1 - CLINICAL T	TRIAL QUESTIONNAIRE:
1.	Does this study	Yes No (If no, stop here)
	involve human participants?	
2.	Are the participants prospectively assigned	Yes No
	to an intervention?	
3.	Is the study a Delayed Onset study?	Yes No
	Delayed onset means you can't fully define	
	your plans for the human subjects study in	
	your application. Typically, this means you	
	need initial results from the first part of the grant before finalizing plans for	
	the human subjects portion.	
4.	Is this study exempt from federal	Yes No
7.	regulations?	105110
	If "Yes" to question 4 above, Circle the	1 2 3 4 5 6 7 8
	appropriate exemption number:	
5.	Is the study designed to evaluate the effect	Yes No
	of the intervention on the participants?	
6.	Is the effect that will be evaluated a health-	Yes No
	related biomedical or behavioral outcome?	
	SECTION 2 – STUDY POPUL	ATION CHARACTERISTICS
1.	<b>Conditions or Focus of the Study</b>	
	Identify the name(s) of the disease(s) or	
	condition(s) you are studying, or the focus	
	of the study.	
	T0 9.11	
	If available, use appropriate descriptors	
	from NLM's Medical Subject Headings	
2.	(MeSH) Eligibility Criteria	
۷.	Engionity Criteria	
3.	<u> </u>	
4.	Inclusion of Women, Minorities, and	Attach as additional document
	Children	

<u>Center of Excellence in Environmental Toxicology (CEET)</u>

<u>Environmental Health Science Focused Research Pilot Project Grant Application</u>

6. Recruitment Status (Please Select One):    Study Timeline	5. Recruitment and Retention Plan – not	Attach as additional document
Recruiting	required if Exempt #4	N1 / / //
Enrolling by invitation Active Not Recruiting Completed Suspended Terminated (Halted prematurely) Withdrawn (No Participants Enrolled)  7. Study Timeline 8. Enrollment of First Subject – Enter the date and if it is Anticipated or Actual  9. Inclusion Enrollment Report – Use template to provide information for manual entry into Penn eRA  SECTION 3 – PROTECTION AND MONITORING PLANS (ATTACH AS ONE SINGLE DOCUMENT)  1. Protection of Human Subjects A Human Subjects A Human Subjects A Human Subjects A Human Subjects Involvement, Characteristics, and Design B. Study Procedures, Materials, and Potential Risks A. Informed Consent and Assent B. Protections Against Risk C. Vulnerable Subjects, if relevant to your study  4. Potential Benefits of the Proposed Research to Research Participants and Others  5. Importance of the Knowledge to be Gained Others  5. Importance of the Knowledge to be Gained G. Is this multi-site?  1. Pata and Safety Monitoring Plan – required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? – required for Clinical Trial, optional for all	6. Recruitment Status (Please Select One):	
Active Not Recruiting Completed Suspended Terminated (Halted prematurely) Withdrawn (No Participants Enrolled)  7. Study Timeline Attach as additional document  8. Enrollment of First Subject – Enter the date and if it is Anticipated or Actual  9. Inclusion Enrollment Report – Use template to provide information for manual entry into Penn eRA  SECTION 3 – PROTECTION AND MONITORING PLANS (ATTACH AS ONE SINGLE DOCUMENT)  1. Protection of Human Subjects Attach as additional document  2. Risks to Human Subjects Involvement, Characteristics, and Design b. Study Procedures, Materials, and Potential Risks  3. Adequacy of Protection Against Risks a. Informed Consent and Assent b. Protections Against Risks c. Vulnerable Subjects, if relevant to your study  4. Potential Benefits of the Proposed Research to Research Participants and Others  5. Importance of the Knowledge to be Gained Others  6. Is this multi-site? Yes No  Attach as additional document		
Not Recruiting		° ;
Completed Suspended Terminated (Halted prematurely) Withdrawn (No Participants Enrolled)  7. Study Timeline 8. Enrollment of First Subject – Enter the date and if it is Anticipated or Actual 9. Inclusion Enrollment Report – Use template to provide information for manual entry into Penn eRA  SECTION 3 – PROTECTION AND MONITORING PLANS (ATTACH AS ONE SINGLE DOCUMENT)  1. Protection of Human Subjects a. Human Subjects   Attach as additional document  Characteristics, and Design b. Study Procedures, Materials, and Potential Risks 3. Adequacy of Protection Against Risks c. Vulnerable Subjects, if relevant to your study  4. Potential Benefits of the Proposed Research to Research Participants and Others  5. Importance of the Knowledge to be Gained 6. Is this multi-site?  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan – required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? – required for Clinical Trial, optional for all other Human Subjects research  Sec attached form  Attach as additional document		
Suspended Terminated (Halted prematurely) Withdrawn (No Participants Enrolled)  7. Study Timeline 8. Enrollment of First Subject – Enter the date and if it is Anticipated or Actual 9. Inclusion Enrollment Report – Use template to provide information for manual entry into Penn eRA  SECTION 3 – PROTECTION AND MONITORING PLANS (ATTACH AS ONE SINGLE DOCUMENT)  1. Protection of Human Subjects  a. Human Subjects  a. Human Subjects Involvement, Characteristics, and Design  b. Study Procedures, Materials, and Potential Risks  3. Adequacy of Protection Against Risks  a. Informed Consent and Assent  b. Protections Against Risks  c. Vulnerable Subjects, if relevant to your study  4. Potential Benefits of the Proposed Research to Research Participants and Others  5. Importance of the Knowledge to be Gained  6. Is this multi-site?  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan – required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? – required for Clinical Trial, optional for all other Human Subjects required for Clinical Trial, optional for all other Human Subjects required for Clinical Trial, optional for all other Human Subjects required for Clinical Trial, optional for all other Human Subjects required for Clinical Trial, optional for all other Human Subjects required for Clinical Trial, optional for all other Human Subjects required for Clinical Trial, optional for all other Human Subjects required for Clinical Trial, optional for all other Human Subjects required for Clinical Trial, optional for all other Human Subjects required for Clinical Trial, optional for all other Human Subjects required for Clinical Trial, optional for all other Human Subjects required for Clinical Trial, optional for all other Human Subjects required for Clinical Trial, optional for all other Human Subjects required for Clinical Trial, optional for all other Human Subjects and the Actual as additional		
Terminated (Halted prematurely) Withdrawn (No Participants Enrolled)  7. Study Timeline 8. Enrollment of First Subject – Enter the date and if it is Anticipated or Actual 9. Inclusion Enrollment Report – Use template to provide information for manual entry into Penn eRA  SECTION 3 – PROTECTION AND MONITORING PLANS (ATTACH AS ONE SINGLE DOCUMENT)  1. Protection of Human Subjects		
Withdrawn (No Participants Enrolled)   Attach as additional document		
7. Study Timeline 8. Enrollment of First Subject – Enter the date and if it is Anticipated or Actual 9. Inclusion Enrollment Report – Use template to provide information for manual entry into Penn eRA  SECTION 3 – PROTECTION AND MONITORING PLANS (ATTACH AS ONE SINGLE DOCUMENT)  1. Protection of Human Subjects		
8. Enrollment of First Subject – Enter the date and if it is Anticipated or Actual  9. Inclusion Enrollment Report – Use template to provide information for manual entry into Penn eRA  SECTION 3 – PROTECTION AND MONITORING PLANS (ATTACH AS ONE SINGLE DOCUMENT)  1. Protection of Human Subjects  a. Human Subjects   Attach as additional document  Characteristics, and Design  b. Study Procedures, Materials, and Potential Risks  3. Adequacy of Protection Against Risk  a. Informed Consent and Assent  b. Protections Against Risk  c. Vulnerable Subjects, if relevant to your study  4. Potential Benefits of the Proposed Research to Research Participants and Others  5. Importance of the Knowledge to be Gained  6. Is this multi-site?   Yes No  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan — required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? – required for Clinical Trial, optional for all	7. Study Timeline	
date and if it is Anticipated or Actual		
9. Inclusion Enrollment Report – Use template to provide information for manual entry into Penn eRA  SECTION 3 – PROTECTION AND MONITORING PLANS (ATTACH AS ONE SINGLE DOCUMENT)  1. Protection of Human Subjects   Attach as additional document   2. Risks to Human Subjects   Attach as additional document	*	
template to provide information for manual entry into Penn eRA  SECTION 3 – PROTECTION AND MONITORING PLANS (ATTACH AS ONE SINGLE DOCUMENT)  1. Protection of Human Subjects   Attach as additional document   2. Risks to Human Subjects   Attach as additional document   3. Human Subjects Involvement, Characteristics, and Design   4. Detential Risks   Attach as additional document   5. Protections Against Risk   6. Vulnerable Subjects, if relevant to your study   6. Is this multi-site?   Yes No   6. Is this multi-site?   Yes No   6. Is the question above, describe the single IRB plan   7. Data and Safety Monitoring Plan - required for Clinical Trial, optional for all   6. Will a Data and Safety Monitoring Board be appointed for this study? - required for Clinical Trial, optional for all   7. Contact   Contact   Contact   Contact   Contact   8. Will a Data and Safety Monitoring Board be appointed for this study? - required for Clinical Trial, optional for all    1. Protection of Human Subjects   Attach as additional document    Attach as additio		See attached form
SECTION 3 – PROTECTION AND MONITORING PLANS (ATTACH AS ONE SINGLE DOCUMENT)  1. Protection of Human Subjects		
1. Protection of Human Subjects 2. Risks to Human Subjects   Attach as additional document   2. Risks to Human Subjects   Attach as additional document   2. Luman Subjects Involvement,   Characteristics, and Design   3. Study Procedures, Materials, and   Potential Risks   3. Adequacy of Protection Against Risks   a. Informed Consent and Assent   3. Protections Against Risk   C. Vulnerable Subjects, if relevant to   your study   4. Potential Benefits of the Proposed   Research to Research Participants and Others   5. Importance of the Knowledge to be Gained   Attach as additional document   6. Is this multi-site?   Yes No   4. If yes to the question above, describe the single IRB plan   7. Data and Safety Monitoring Plan -   required for Clinical Trial, optional for all other Human Subjects research   8. Will a Data and Safety Monitoring Board   Yes No      Yes No   No	manual entry into Penn eRA	
1. Protection of Human Subjects 2. Risks to Human Subjects 3. Human Subjects Involvement, Characteristics, and Design b. Study Procedures, Materials, and Potential Risks 3. Adequacy of Protection Against Risks a. Informed Consent and Assent b. Protections Against Risk c. Vulnerable Subjects, if relevant to your study 4. Potential Benefits of the Proposed Research to Research Participants and Others 5. Importance of the Knowledge to be Gained 6. Is this multi-site?  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan — required for Clinical Trial, optional for all other Human Subjects research B. Will a Data and Safety Monitoring Board be appointed for this study? — required for Clinical Trial, optional for all	SECTION 3 – PROTECTION AND MONIT	ORING PLANS (ATTACH AS ONE SINGLE
2. Risks to Human Subjects a. Human Subjects Involvement, Characteristics, and Design b. Study Procedures, Materials, and Potential Risks  3. Adequacy of Protection Against Risks a. Informed Consent and Assent b. Protections Against Risk c. Vulnerable Subjects, if relevant to your study  4. Potential Benefits of the Proposed Research to Research Participants and Others  5. Importance of the Knowledge to be Gained 6. Is this multi-site?  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan — required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? — required for Clinical Trial, optional for all	DOCU	,
a. Human Subjects Involvement, Characteristics, and Design b. Study Procedures, Materials, and Potential Risks  3. Adequacy of Protection Against Risks a. Informed Consent and Assent b. Protections Against Risk c. Vulnerable Subjects, if relevant to your study  4. Potential Benefits of the Proposed Research to Research Participants and Others  5. Importance of the Knowledge to be Gained 6. Is this multi-site?  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan — required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? — required for Clinical Trial, optional for all	1. Protection of Human Subjects	
Characteristics, and Design b. Study Procedures, Materials, and Potential Risks  3. Adequacy of Protection Against Risks a. Informed Consent and Assent b. Protections Against Risk c. Vulnerable Subjects, if relevant to your study  4. Potential Benefits of the Proposed Research to Research Participants and Others  5. Importance of the Knowledge to be Gained 6. Is this multi-site?  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan — required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? — required for Clinical Trial, optional for all	J	Attach as additional document
b. Study Procedures, Materials, and Potential Risks  3. Adequacy of Protection Against Risks a. Informed Consent and Assent b. Protections Against Risk c. Vulnerable Subjects, if relevant to your study  4. Potential Benefits of the Proposed Research to Research Participants and Others  5. Importance of the Knowledge to be Gained 6. Is this multi-site?  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan — required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? — required for Clinical Trial, optional for all		
Potential Risks  3. Adequacy of Protection Against Risks a. Informed Consent and Assent b. Protections Against Risk c. Vulnerable Subjects, if relevant to your study  4. Potential Benefits of the Proposed Research to Research Participants and Others  5. Importance of the Knowledge to be Gained 6. Is this multi-site?  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan — required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? — required for Clinical Trial, optional for all		
3. Adequacy of Protection Against Risks a. Informed Consent and Assent b. Protections Against Risk c. Vulnerable Subjects, if relevant to your study  4. Potential Benefits of the Proposed Research to Research Participants and Others  5. Importance of the Knowledge to be Gained 6. Is this multi-site?  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan — required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? — required for Clinical Trial, optional for all	•	
a. Informed Consent and Assent b. Protections Against Risk c. Vulnerable Subjects, if relevant to your study  4. Potential Benefits of the Proposed Research to Research Participants and Others  5. Importance of the Knowledge to be Gained 6. Is this multi-site?  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan — required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? — required for Clinical Trial, optional for all		
b. Protections Against Risk c. Vulnerable Subjects, if relevant to your study  4. Potential Benefits of the Proposed Research to Research Participants and Others  5. Importance of the Knowledge to be Gained 6. Is this multi-site?  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan – required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? – required for Clinical Trial, optional for all		Attach as additional document
c. Vulnerable Subjects, if relevant to your study  4. Potential Benefits of the Proposed Research to Research Participants and Others  5. Importance of the Knowledge to be Gained 6. Is this multi-site?  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan — required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? — required for Clinical Trial, optional for all		
your study  4. Potential Benefits of the Proposed Research to Research Participants and Others  5. Importance of the Knowledge to be Gained 6. Is this multi-site?  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan — required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? — required for Clinical Trial, optional for all	· ·	
4. Potential Benefits of the Proposed Research to Research Participants and Others  5. Importance of the Knowledge to be Gained 6. Is this multi-site?  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan — required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? — required for Clinical Trial, optional for all	*	
Research to Research Participants and Others  5. Importance of the Knowledge to be Gained 6. Is this multi-site?  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan — required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? — required for Clinical Trial, optional for all	· · ·	
5. Importance of the Knowledge to be Gained 6. Is this multi-site?  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan — required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? — required for Clinical Trial, optional for all		Attach as additional document
5. Importance of the Knowledge to be Gained 6. Is this multi-site?  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan — required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? — required for Clinical Trial, optional for all	_	
6. Is this multi-site?  If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan — required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? — required for Clinical Trial, optional for all		
If yes to the question above, describe the single IRB plan  7. Data and Safety Monitoring Plan — required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? — required for Clinical Trial, optional for all		
7. Data and Safety Monitoring Plan — required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? — required for Clinical Trial, optional for all		
<ul> <li>7. Data and Safety Monitoring Plan – required for Clinical Trial, optional for all other Human Subjects research</li> <li>8. Will a Data and Safety Monitoring Board be appointed for this study? – required for Clinical Trial, optional for all</li> </ul>	_	Attach as additional document
required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? – required for Clinical Trial, optional for all	single IKB plan	
required for Clinical Trial, optional for all other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? – required for Clinical Trial, optional for all	7 Data and Safety Manitoring Plan	Attach as additional document
other Human Subjects research  8. Will a Data and Safety Monitoring Board be appointed for this study? – required for Clinical Trial, optional for all	•	Actaon as additional document
8. Will a Data and Safety Monitoring Board be appointed for this study? – required for Clinical Trial, optional for all		
be appointed for this study? — required for Clinical Trial, optional for all		Ves No
Clinical Trial, optional for all		103110
· ·		
	· •	
9. Overall structure of the study team - Attach as additional document		Attach as additional document
required for Clinical Trial, optional for all	· ·	
other Human Subjects research		

Environmental Health Science Focused Research Pilot Project Grant Application

#### **APPLICATION REVIEW CRITERIA:**

Applications will be sent out for peer-review to experts in the field, the CEET Executive Committee will then meet to select the awardees.

The major review criteria are and will be scored using the NIH system

- 1. Significance
- 2. Approach
- 3. Innovation
- 4. Investigator
- 5. Resources & Environment
- 6. Budget/Budget Justification
- 7. Likelihood that the project will lead to NIEHS/NIH grant support

Funding will begin **Friday, October 1, 2021** and a Notification of award will be sent to the P.I. and their B.A. **by Friday, September 24, 2021**.

Each application will receive a decision letter and a copy of the critique and scores. If an applicant is encouraged to reapply they must provide a response to the critique (no more than one page).

For questions or more information, contact: Paula Williams (215) 746-3031

paula.williams@pennmedicine.upenn.edu